Atrial fibrillation risk of ibrutinib compared with that of chemotherapy, targeted therapy, and next-generation Bruton's tyrosine kinase inhibitors: Updated systematic review and meta-analysis

Shi Jiale, Li Wei, Liang Huazhen, Gong Hui-ping